Genmab A/S
CSE:GMAB
Genmab A/S
Common Stock
Genmab A/S
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Common Stock
kr66m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Common Stock
kr71m
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Common Stock
€2.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
229%
|
CAGR 10-Years
101%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Common Stock
kr788.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Common Stock
kr429.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
|
Saniona AB
STO:SANION
|
Common Stock
kr5.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
32%
|
CAGR 10-Years
23%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Common Stock?
Common Stock
66m
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Common Stock amounts to 66m DKK.
What is Genmab A/S's Common Stock growth rate?
Common Stock CAGR 10Y
1%
Over the last year, the Common Stock growth was 0%.
You don't have any saved screeners yet